 Diabetic Nephropathies
"Diabetic Nephropathies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Descriptor ID |
D003928
|
| MeSH Number(s) |
C12.777.419.192 C13.351.968.419.192 C19.246.099.875
|
| Concept/Terms |
Diabetic Nephropathies- Diabetic Nephropathies
- Nephropathies, Diabetic
- Nephropathy, Diabetic
- Diabetic Nephropathy
- Diabetic Kidney Disease
- Diabetic Kidney Diseases
- Kidney Disease, Diabetic
- Kidney Diseases, Diabetic
Diabetic Glomerulosclerosis- Diabetic Glomerulosclerosis
- Kimmelstiel-Wilson Syndrome
- Kimmelstiel Wilson Syndrome
- Syndrome, Kimmelstiel-Wilson
- Kimmelstiel-Wilson Disease
- Kimmelstiel Wilson Disease
- Nodular Glomerulosclerosis
- Glomerulosclerosis, Nodular
- Glomerulosclerosis, Diabetic
- Intracapillary Glomerulosclerosis
|
Below are MeSH descriptors whose meaning is more general than "Diabetic Nephropathies".
Below are MeSH descriptors whose meaning is more specific than "Diabetic Nephropathies".
This graph shows the total number of publications written about "Diabetic Nephropathies" by people in this website by year, and whether "Diabetic Nephropathies" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 0 | 1 | 1 | | 1990 | 1 | 1 | 2 | | 1991 | 2 | 0 | 2 | | 1992 | 2 | 2 | 4 | | 1993 | 5 | 2 | 7 | | 1994 | 4 | 0 | 4 | | 1995 | 3 | 3 | 6 | | 1996 | 4 | 0 | 4 | | 1997 | 6 | 3 | 9 | | 1998 | 5 | 1 | 6 | | 1999 | 1 | 2 | 3 | | 2000 | 5 | 1 | 6 | | 2001 | 1 | 0 | 1 | | 2002 | 4 | 2 | 6 | | 2003 | 9 | 2 | 11 | | 2004 | 6 | 4 | 10 | | 2005 | 3 | 1 | 4 | | 2006 | 3 | 1 | 4 | | 2007 | 6 | 1 | 7 | | 2008 | 6 | 2 | 8 | | 2009 | 4 | 16 | 20 | | 2010 | 8 | 2 | 10 | | 2011 | 4 | 4 | 8 | | 2012 | 2 | 0 | 2 | | 2013 | 4 | 2 | 6 | | 2014 | 5 | 3 | 8 | | 2015 | 4 | 2 | 6 | | 2016 | 6 | 0 | 6 | | 2017 | 2 | 0 | 2 | | 2018 | 7 | 2 | 9 | | 2019 | 6 | 0 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Diabetic Nephropathies" by people in Profiles.
-
Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):345-356.
-
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):333-344.
-
Bakris GL. Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors. Am J Kidney Dis. 2019 11; 74(5):573-575.
-
Rossing P, Block GA, Chin MP, Goldsberry A, Heerspink HJL, McCullough PA, Meyer CJ, Packham D, Pergola PE, Spinowitz B, Sprague SM, Warnock DG, Chertow GM. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. Kidney Int. 2019 10; 96(4):1030-1036.
-
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 06 13; 380(24):2295-2306.
-
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 05 11; 393(10184):1937-1947.
-
de Zeeuw D, Renfurm RW, Bakris G, Rossing P, Perkovic V, Hou FF, Nangaku M, Sharma K, Heerspink HJL, Garcia-Hernandez A, Larsson TE. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2018 12; 6(12):925-933.
-
Cimeno A, Munley J, Drachenberg C, Weir M, Haririan A, Bromberg J, Barth RN, Scalea JR. Diabetic nephropathy after kidney transplantation in patients with pretransplantation type II diabetes: A retrospective case series study from a high-volume center in the United States. Clin Transplant. 2018 12; 32(12):e13425.
-
Chertow GM, Appel GB, Block GA, Chin MP, Coyne DW, Goldsberry A, Kalantar-Zadeh K, Meyer CJ, Molitch ME, Pergola PE, Raskin P, Silva AL, Spinowitz B, Sprague SM, Rossing P. Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. J Diabetes Complications. 2018 Dec; 32(12):1113-1117.
-
Pitt B, Bakris GL, Weir MR, Freeman MW, Lainscak M, Mayo MR, Garza D, Zawadzki R, Berman L, Bushinsky DA. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail. 2018 08; 5(4):592-602.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|